Disclosed is a means for developing a compound which has no teratogenicity while retaining a useful activity. Specifically disclosed is a method for screening for a non-teratogenic substance, which is characterized by comprising: bringing each of test substances into contact with cerebron or a fragment thereof evaluating the bindability of the test substances to cerebron or the fragment thereof and selecting a test substance that does not bind to cereblon or the fragment thereof or a test substance that has lower bindability to cereblon or the fragment thereof compared to that of thalidomide.
